Free Trial
→ Why Some AI Stocks Already Surged Over 300 Percent (From Brownstone Research) (Ad)tc pixel
NASDAQ:OMER

Omeros Q3 2026 Earnings Date & Estimates

Omeros logo
$16.20 -2.59 (-13.78%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$16.30 +0.10 (+0.62%)
As of 10/16/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Omeros is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Omeros in Q3 2026

Omeros is expected to post earnings of $0.03 per share on revenue of $37.28 million. In the same quarter a year earlier Omeros reported -$0.19 per share. Omeros last reported on August 12, 2026, posting $0.02 per share and beating the -$0.2683 consensus estimate. Omeros has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.03
Expected Revenue
$37.28 million
Prior-Year EPS
-$0.19

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.02 (Beat by +$0.2883)
Last Quarter Revenue
$28.53 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Omeros Q3 2026 Earnings FAQ

Omeros (NASDAQ:OMER) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Omeros' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Omeros to post earnings of $0.03 per share for Q3 2026.

The consensus revenue estimate for Omeros is $37.28 million for Q3 2026.

Omeros Earnings Headlines

Omeros shares fall 4% as European regulators uphold negative opinion on Narsoplimab
October 17 at 5:18 PM  |  msn.comhttps://www.msn.com/en-us/money/financial-regulation/omeros-shares-fall-4-as-european-regulators-uphold-negative-opinion-on-narsoplimab/ar-AA2enRA6
Omeros Stock Falls 12% After EMA Committee Reaffirms Negative Narsoplimab Opinion
October 17 at 12:17 PM  |  rttnews.comhttps://www.rttnews.com/3699845/omeros-stock-falls-12-after-ema-committee-reaffirms-negative-narsoplimab-opinion.aspx
Why Some AI Stocks Already Surged Over 300 Percent
Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run, and Vertiv before a 1900 percent run. Now he's tracking a radical light-speed technology that could make AI 100 times faster and 100 times more energy efficient. Stocks tied to it have already climbed 133 percent, 217 percent, and 320 percent.tc pixel
October 18 at 1:00 AM  |  Brownstone Research (Ad)
Update: Omeros Shares Fall After Narsoplimab Application Rejected Again by EU Agency
October 16 at 6:55 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/omeros-shares-fall-narsoplimab-application-182507668.html
Omeros shares slide after CHMP upholds negative opinion on drug; analyst sees buying opportunity at $16
October 16 at 6:55 PM  |  msn.comhttps://www.msn.com/en-in/news/other/omeros-shares-slide-after-chmp-upholds-negative-opinion-on-drug-analyst-sees-buying-opportunity-at-16/ar-AA2eobPc
Omeros Says European Medicines Agency Upholds Negative Opinion on Narsoplimab Application -- Update
October 16 at 6:55 PM  |  marketwatch.comhttps://www.marketwatch.com/story/omeros-says-european-medicines-agency-upholds-negative-opinion-on-narsoplimab-application-update-a8c623e9
See More Omeros Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Omeros? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Omeros and other key companies, straight to your email.

About Omeros

Omeros (NASDAQ:OMER) (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway. Omeros conducts research and clinical development primarily from the United States, with clinical programs potentially involving international sites. Gregory A. Demopulos, M.D., is the company’s founder, chairman and chief executive officer.

View Omeros Profile
Earnings Tools